Selected aspects of genetic counselling for BRCA1 mutation carriers

Table 7 Relationship between tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

Parameters	Case (n = 285)	Control (n = 751)	Univariate analysis			Multivariate analysis
			OR	95% CI	p	OR	95% CI	p
All carriers: tamoxifen, n
never	250	566	1.00			1.00
ever	35	185	0.45	0.29-0.70	0.0004	0.47	0.30-0.74	0.001
BRCA1 carriers: tamoxifen, n
never	204	483	1.00			1.00
ever	24	138	0.48	0.29-0.79	0.004	0.50	0.03-0.85	0.01
BRCA2 carriers: tamoxifen, n
never	46	83	1.00			1.00
ever	11	48	0.39	0.16-0.94	0.003	0.42	0.17-1.02	0.05

ISSN: 1897-4287